COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

One year into the Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), effective treatments are still needed(1-3). Monoclonal antibodies, given alone or as part of a therapeutic cocktail, have shown promising results in patients, raisin...

Descripción completa

Detalles Bibliográficos
Autores principales: Maisonnasse, P, Aldon, Y, Marc, A, Marlin, R, Dereuddre-Bosquet, N, Kuzmina, NA, Freyn, AW, Snitselaar, JL, Gonçalves, A, Caniels, TG, Burger, JA, Poniman, M, Chesnais, V, Diry, S, Iershov, A, Ronk, AJ, Jangra, S, Rathnasinghe, R, Brouwer, PJM, Bijl, TPL, van Schooten, J, Brinkkemper, M, Liu, H, Yuan, M, Mire, CE, van Breemen, MJ, Contreras, V, Naninck, T, Lemaître, J, Kahlaoui, N, Relouzat, F, Chapon, C, Ho Tsong Fang, R, McDanal, C, Osei-Twum, M, St-Amant, N, Gagnon, L, Montefiori, DC, Wilson, IA, Ginoux, E, de Bree, GJ, García-Sastre, A, Schotsaert, M, Coughlan, L, Bukreyev, A, van der Werf, S, Guedj, J, Sanders, RW, van Gils, MJ, Le Grand, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899470/
https://www.ncbi.nlm.nih.gov/pubmed/33619476
http://dx.doi.org/10.21203/rs.3.rs-235272/v1

Ejemplares similares

Ejemplares similares